Evidence map›Paper›PMID 32350071›Full record

ArticleJournal of virology2020

Influence of Human Cytomegalovirus Glycoprotein O Polymorphism on the Inhibitory Effect of Soluble Forms of Trimer- and Pentamer-Specific Entry Receptors.

Nadja Brait, Tanja Stögerer, Julia Kalser, Barbara Adler, Ines Kunz, Max Benesch, Barbara Kropff, Michael Mach, Elisabeth Puchhammer-Stöckl, Irene Görzer

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nadja Brait *Center for Virology, Medical University of Vienna, Vienna, Austria.
Tanja Stögerer *Center for Virology, Medical University of Vienna, Vienna, Austria.
Julia KalserCenter for Virology, Medical University of Vienna, Vienna, Austria.
Barbara AdlerMax von Pettenkofer Institute for Virology, Ludwig Maximilians University Munich, Munich, Germany.
Ines KunzCenter for Virology, Medical University of Vienna, Vienna, Austria.
Max BeneschCenter for Virology, Medical University of Vienna, Vienna, Austria.
Barbara KropffVirologisches Institut, Klinische und Molekulare Virologie, Friedrich Alexander Universität Erlangen Nürnberg, Erlangen, Germany.
Michael MachVirologisches Institut, Klinische und Molekulare Virologie, Friedrich Alexander Universität Erlangen Nürnberg, Erlangen, Germany.
Elisabeth Puchhammer-StöcklCenter for Virology, Medical University of Vienna, Vienna, Austria.
Irene GörzerCenter for Virology, Medical University of Vienna, Vienna, Austria irene.goerzer@meduniwien.ac.at.
Medical University of Vienna · ATFriedrich-Alexander-Universität Erlangen-Nürnberg · DELudwig-Maximilians-Universität München · DE

Funding

Austrian Science Fund FWF P 26420
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) envelope glycoprotein complexes, gH/gL/gO trimer and gH/gL/UL128-131 pentamer, are important for cell-free HCMV entry. While soluble NRP2-Fc (sNRP2-Fc) interferes with epithelial/endothelial cell entry through UL128, soluble platelet-derived growth factor receptor α-Fc (sPDGFRα-Fc) interacts with gO, thereby inhibiting infection of all cell types. Since gO is the most variable subunit, we investigated the influence of gO polymorphism on the inhibitory capacities of sPDGFRα-Fc and sNRP2-Fc. Accordingly, gO genotype 1c (GT1c) sequence was fully or partially replaced by gO GT2b, GT3, and GT5 sequences in the bacterial artificial chromosome (BAC) TB40-BAC4-luc background (where luc is luciferase). All mutants were tested for fibroblast and epithelial cell infectivity, for virion content of gB, gH, and gO, and for infection inhibition by sPDGFRα-Fc and sNRP2-Fc. Full-length and partial gO GT swapping may increase epithelial-to-fibroblast ratios due to subtle alterations in fibroblast and/or epithelial infectivity but without substantial changes in gB and gH levels in mutant virions. All gO GT mutants except recombinant gO GT1c/3 displayed a nearly complete inhibition at 1.25 μg/ml sPDGFRα-Fc on epithelial cells (98% versus 91%), and all experienced complete inhibition on fibroblasts (≥99%). While gO GT replacement did not influence sNRP2-Fc inhibition at 1.25 μg/ml on epithelial cells (97% to 99%), it rendered recombinant mutant GT1c/3 moderately accessible to fibroblast inhibition (40%). In contrast to the steep sPDGFRα-Fc inhibition curves (slope of >1.0), sNRP2-Fc dose-response curves on epithelial cells displayed slopes of ∼1.0, suggesting functional differences between these entry inhibitors. Our findings demonstrate that artificially generated gO recombinants rather than the major gO genotypic forms may affect the inhibitory capacities of sPDGFRα and sNRP2 in a cell type-dependent manner.

Indexed as

CytomegalovirusMembrane GlycoproteinsNeuropilin-2Polymorphism, GeneticProtein MultimerizationViral Envelope ProteinsVirus InternalizationFibroblastsHumansRecombinant Fusion ProteinsSolubilityglycoprotein O, cytomegalovirusMembrane GlycoproteinsNeuropilin-2neuropilin-2, humanRecombinant Fusion ProteinsViral Envelope Proteinsenvelope glycoproteinsgenetic recombinationgO genotypeshuman cytomegalovirusstrain diversityvirus entry

Identifiers

PMID32350071
PMCPMC7343208
OpenAlexW3019953576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.